Merck & Co., Inc. (NYSE: MRK) — A Crown Jewel With a 2028 Expiry Date, Priced for the Funeral and an Option on the Wake

An independent fundamental research note Report date: 2026-06-11 Price (2026-06-10): $119.09 · Market cap: ~$296B · Enterprise value: ~$340B · Net debt: ~$35B Fiscal year: December · CIK: 0000310158 · Shares (diluted): ~2.48B · Dividend yield: ~2.8%

⚡ Claude’s Take

This block is the author’s own independent opinion and general information only — not investment advice and not a recommendation to buy or sell any security. The analysis that follows takes no position and names no price target; do your own research.

Verdict: HOLD — accumulate on weakness below ~$100; trim toward ~$135. Conviction: medium. Tag: “Best house in a neighborhood with a demolition notice.”

Merck is one of the highest-quality cash machines in global pharma — ~82% gross margins, mid-30s% ROE, a $12B+ free-cash-flow base, and the single most successful drug in the industry’s history. It is also a company where one molecule, Keytruda, is ~49% of revenue and a clear majority of profit, and that molecule walks off a U.S. patent cliff in December 2028, with Medicare price-setting hitting it from January 2029 regardless of how the patent litigation breaks. The entire investment debate compresses to one question: can the bought-and-built replacement portfolio fill a ~$15–20B revenue hole before the market’s patience runs out?

At ~$119 the stock trades at ~12.5× forward clean earnings (the headline 33× trailing P/E and “rich vs. history” screens are artifacts of one-time IPR&D charges that gut GAAP EPS — see the Financial Quality and Valuation sections). That is cheaper than AbbVie (~14×), far cheaper than J&J (~19×) or Lilly (~26×), and only a notch above cliff-stricken Bristol Myers (~9×). The market is pricing Merck as a slow-motion melting franchise, not a compounder. I think that is roughly fair, leaning slightly too pessimistic — but not the screaming bargain the bulls claim. Merck has more shots on goal than Bristol did (Winrevair, the Daiichi ADCs, oral PCSK9, sac-TMT, subcutaneous Keytruda, an animal-health jewel), a genuinely elite commercialization engine (Winrevair’s launch proves it), and a 13× multiple that already discounts a hard landing. But the replacement pipeline is mostly acquired, largely pre-scale, and unproven — the $70B “phoenix” number management touts is explicitly non-risk-adjusted — Gardasil’s China engine is structurally broken, and not one insider has bought a share in the open market while the stock sat near multi-year lows. That last fact keeps me at HOLD rather than BUY. The framing is deep-value-with-a-clock: you are paid ~2.8% to wait, you own a fortress balance sheet, and you have a free option on a 2026–2027 readout cluster (TL1A, the ADCs, Winrevair-in-HFpEF, enlicitide) that could re-rate the stock. You are also exposed to the possibility that breadth is not the same as scale, and that 13× becomes 11× on falling earnings.

What flips me bullish: the 2026–2027 pipeline de-risking lands — two or three of {tulisokibart Phase 3, the Daiichi ADCs, Winrevair HYPERION/HFpEF, oral PCSK9 enlicitide, sac-TMT} convert to approvable blockbusters, making the post-cliff bridge visible before Keytruda falls (the AbbVie playbook). What flips me bearish: Qlex subcutaneous conversion stalls against payer step-edits to cheap biosimilars, and/or the marquee clinical bets (TL1A, MK-1406, the ADCs) miss — confirming Merck overpaid for binary optionality under a deadline and that the cliff is a true earnings cliff, not a speed bump.

1. Executive Summary

Merck & Co. is a $65B-revenue, ~$296B-market-cap global pharmaceutical and animal-health company built around the most commercially successful drug ever launched, the PD-1 immunotherapy Keytruda (pembrolizumab), which generated $31.7B in 2025 — 49% of total company revenue and ~55% of the Pharmaceutical segment. The company earns ~82% gross margins, converts roughly 0.9–1.0× of net income to operating cash flow in clean years (~$16.5B OCF, ~$12.4B free cash flow in 2025), and earns mid-30s% returns on equity. By the metrics that matter — margin structure, pricing power, return on capital — this is an exceptional business today.

The thesis is not about today; it is about 2028–2029. Keytruda’s primary U.S. composition-of-matter patent expires in December 2028, opening the door to biosimilar pembrolizumab; even if two follow-on patents push biosimilar entry toward mid/late-2029, IRA Medicare price negotiation begins to bite from January 2029 regardless. Merck is therefore racing to replace ~$15–20B of high-margin revenue. Its defenses are (a) Keytruda Qlex, a subcutaneous reformulation it hopes converts 30–40% of IV volume and carries fresh formulation IP; (b) a fast-ramping cardiopulmonary franchise led by Winrevair (sotatercept, PAH, $1.44B in its first full year); and © a large, mostly acquired late-stage pipeline — the Daiichi Sankyo antibody-drug-conjugates, sac-TMT (TROP2 ADC), oral PCSK9 enlicitide, the TL1A program from Prometheus, a long-acting flu antiviral from Cidara, and Ohtuvayre (COPD) from the $10B Verona deal. Management frames this as “over $70 billion of commercial opportunity by the mid-2030s” — but that figure is explicitly non-risk-adjusted and back-end-loaded.

The bear case is structural and credible: Merck is a serial-patent-cliff treadmill entering its hardest cliff with a replacement portfolio that is largely pre-scale and bought at high prices under deadline pressure (Marathon’s “urgency destroys discipline”), while a second pillar — Gardasil, the HPV vaccine — has been structurally impaired by a China shipment halt and a new domestic Chinese competitor (revenue −39% in 2025). The bull case is that the market, at ~12.5× forward clean earnings, is already pricing a hard landing, and that Merck’s commercialization machine plus 20+ shots on goal will out-diversify the concentration over time.

Valuation is the crux of an otherwise high-quality story. On clean (ex-IPR&D-charge) earnings of roughly $8.7–9.0 for 2026, MRK trades at ~13×, near the cheap end of its own decade history and of large-cap pharma. The reported trailing P/E of 33×, the “76th–91st percentile rich” screen readings, and the 23× forward GAAP figure are all distorted by Merck’s unusual practice of expensing — and not adding back — multi-billion-dollar acquired-IPR&D charges (a $9.0B / $3.62-per-share Cidara charge produced a Q1-2026 GAAP loss). We render no recommendation and set no price target in this body; we frame the security as a high-quality franchise whose entire risk/reward turns on the credibility of a 2026–2027 pipeline-de-risking cluster against a known 2028 cliff.

2. Business Overview

Merck operates two reportable segments. The dominant Pharmaceutical segment ($58.1B, 89.4% of 2025 revenue) develops, manufactures and sells human-health prescription drugs and vaccines to wholesalers, retailers, hospitals, government agencies, and managed-care organizations across oncology, vaccines, cardio-pulmonary, hospital/specialty, immunology, infectious disease, and neuroscience. The smaller Animal Health segment ($6.35B, 9.8%) sells veterinary pharmaceuticals and vaccines plus a digital livestock-monitoring/identification business (Allflex), split between Livestock ($3.90B) and Companion Animal ($2.46B). A residual “Other” line contributed $0.5B.

How Merck makes money. The economic engine is patent-protected branded drugs sold at high gross margin (~82% non-GAAP) during their period of exclusivity, with the cash flow recycled into R&D and business development to generate the next generation of protected products. The model is structurally a treadmill: every molecule is a depreciating asset whose economics collapse at loss of exclusivity (LOE), so durable value lives in the engine — the R&D + commercialization + business-development machine — not in any single product.

The franchises (2025 sales):

• Oncology / Keytruda ($31.7B, +7.5%) — the anchor. A PD-1 checkpoint inhibitor approved in 44 FDA indications across 19 tumor types plus two tumor-agnostic settings, increasingly used in earlier-stage (adjuvant/perioperative) cancer where durability of use is high. Includes the new subcutaneous Keytruda Qlex ($128M in Q1-2026, ramping). Oncology also includes Welireg ($716M, +41%), the AstraZeneca-partnered Lynparza ($1.45B alliance revenue) and Eisai-partnered Lenvima ($1.05B).
• Vaccines — Gardasil/Gardasil 9 HPV ($5.2B, −39%), the ProQuad/M-M-R II/Varivax pediatric MMR-V franchise ($2.45B, stable), Vaxneuvance ($825M) and the newer Capvaxive ($759M, +>100%) pneumococcal vaccines, RotaTeq, Pneumovax 23 ($166M, declining), and the newly launched RSV infant antibody Enflonsia/clesrovimab ($100M).
• Cardiometabolic / cardiopulmonary — Winrevair ($1.44B, +244%) is the growth jewel; the legacy diabetes franchise Januvia/Janumet ($2.54B) faces U.S. LOE in 2026 and IRA price-setting; the new COPD product Ohtuvayre ($178M partial year, from the Verona acquisition).
• Hospital / specialty — Bridion ($1.84B, sugammadex, now facing generics), Prevymis ($978M, +25%), the HIV franchise (Isentress, Delstrigo, Pifeltro, the new IDVYNSO), Lagevrio (COVID antiviral, $380M, −61% and fading).
• Animal Health ($6.35B, +8%) — a genuinely diversified, non-patent-cliff, mid-single-digit grower across livestock vaccines/parasiticides and companion-animal products (Bravecto, the Sentinel line), plus Allflex monitoring.

Recurring vs. at-risk revenue. Vaccines and Animal Health are the most durable (sticky, manufacturing-moated, demographically driven). At risk: Keytruda (2028 cliff), Gardasil (China, structural), Januvia/Janumet (2026 LOE + IRA), Bridion (generics), Lagevrio (declining). The uncomfortable truth is that the durable parts are not large enough to carry the company, and the largest part (Keytruda) is the most at-risk.

Verdict: A superb, high-margin, cash-generative pharmaceutical franchise — but one whose revenue base is dangerously concentrated in a single asset with a known expiry date, supported by a high-quality but sub-scale Animal Health business and a vaccine portfolio whose growth pillar (Gardasil) has cracked.

3. Industry Dynamics

Branded biopharmaceuticals is one of the most profitable industries in the economy within the window of patent exclusivity, and one of the most brutally mean-reverting at its edges. The structure is oligopolistic within therapeutic niches, protected by a triple moat of patents, regulatory approval barriers, and accumulated clinical evidence — but every one of those protections is time-boxed. At LOE, small-molecule generics erode 80%+ of branded sales within 12–18 months, and biosimilars (for biologics like Keytruda) take share more slowly but inexorably, at 15–40% discounts. AbbVie’s Humira provides the canonical case: Humira fell −49.5% in two years of U.S. biosimilar competition. This is not a risk; it is the industry’s physics.

Profit pools and competitive intensity. Oncology immuno-therapy (IO) and immunology are the richest pools and therefore the most crowded. Merck’s Keytruda dominates PD-1 (vs. Bristol Myers’ Opdivo at ~$9–10B and Roche’s Tecentriq at ~$4B), but the next battlegrounds Merck is contesting — PD-1×VEGF bispecifics, TROP2 antibody-drug conjugates, TL1A in inflammatory bowel disease — are arms races with Summit/Akeso, AstraZeneca/Daiichi, Gilead, Roche, and others all crowding in. Marathon’s capital-cycle lens is instructive: abnormally high IO returns have attracted enormous capital, and that capital will compete those returns down. Merck is both a beneficiary of the cycle (Keytruda’s historical economics) and, increasingly, a victim of it (its core niches getting contested just as it needs them to deliver).

Regulation is the structural headwind, and it is intensifying. The Inflation Reduction Act’s Medicare Drug Price Negotiation Program is the defining policy overhang. Januvia was in the first negotiation cohort (government-set price effective January 1, 2026); Janumet is in the second (effective January 2027). Critically, biologics become negotiation-eligible 13 years post-approval — Keytruda (approved 2014) is eligible, and a negotiated price could plausibly take effect around 2028–2029, coinciding with its patent cliff. Separately, the IRA’s Part D redesign is already compressing net prices on launch products — management explicitly cited it cutting Winrevair and Welireg U.S. net pricing in 2025. “Most-favored-nation” pricing proposals and chronic PBM gross-to-net erosion grind realized prices lower even where list prices hold. One modest offset: the new Commissioner’s National Priority Voucher (CNPV) program granted expedited-review vouchers to enlicitide and sac-TMT, tied to U.S. public-health priority and domestic manufacturing.

Verdict: structurally attractive but visibly deteriorating — the same conclusion that applies to AbbVie’s Humira cliff. Branded pharma retains the best in-window economics in the economy, but IRA/MFN net-price compression, the inescapable patent treadmill, and capital crowding into the richest niches make the industry a lower-quality version of itself than it was five years ago. Merck sits at the hard end of this spectrum: a single ~49%-of-revenue asset facing a synchronized 2028–2029 patent-plus-IRA double-hit, with a replacement portfolio still mostly pre-scale.

4. Competitive Position

Name the moat. Merck’s durable advantage is intangible assets (patents, brands, and an unmatched clinical-evidence base) reinforced by economies of scale in R&D and oncology commercial infrastructure. It is explicitly not a network-effect or customer-switching-cost business at the molecule level — a prescriber switches to a biosimilar the moment payers and economics dictate.

Keytruda’s moat — real, financially visible, and patent-bounded. While the patent holds, Keytruda exhibits a genuine, measurable competitive advantage that passes Greenwald’s tests. Its moat mechanism is a clinical-evidence flywheel: 44 approved indications, an unmatched global trial machine (Merck runs hundreds of Keytruda studies), and first-mover entrenchment in the high-value adjuvant/perioperative settings where treatment durations are long and switching is clinically conservative. The financial fingerprints of the moat are unambiguous — ~82% gross margins, intact pricing power, and stable-to-growing market share against Opdivo and Tecentriq (Greenwald’s market-share-stability test passed). This is a real moat by the firm’s standard: remove the patent and the economics deteriorate, which is precisely the point.

But the moat does not survive LOE — and the defense is weaker than AbbVie’s was. Biosimilar pembrolizumab is therapeutically identical, and Keytruda’s 44-indication evidence base becomes a public good that biosimilars free-ride on. Merck’s principal defense, Keytruda Qlex (subcutaneous pembrolizumab co-formulated with a hyaluronidase enzyme, using Alteogen/Halozyme-class technology), is a reformulation of the same molecule, not a differentiated successor drug. Management targets converting 30–40% of IV volume to Qlex by 2028, and has deliberately priced Qlex to drive that switch; the subcutaneous form carries fresh formulation IP that extends past the 2028 IV compound-patent expiry. This is materially weaker than AbbVie’s defense of Humira, where AbbVie had genuinely new molecules (Skyrizi + Rinvoq) already at $25.9B and growing >40% before Humira fell. Merck is defending the same molecule in a new syringe. Even flawless execution — 40% conversion, IP holding, convenience beating payer step-edits — protects only ~30–40% of the franchise; the other 60–70% faces the cliff. And the payer logic is hostile: once a cheaper biosimilar IV exists, PBMs have every incentive to mandate it, the convenience-of-injection argument notwithstanding.

The vaccine moat is cracking where it mattered most. Gardasil 9 is the world’s dominant 9-valent HPV vaccine, protected by manufacturing complexity, regulatory barriers, and a decade of real-world data. But a domestically produced Chinese 9-valent HPV vaccine was approved by the NMPA in June 2025 — the first credible local competitor in Gardasil’s single largest ex-U.S. growth market, a structural impairment layered on top of the inventory glut that halted shipments (see Changes and Headwinds). Elsewhere, Bridion (sugammadex) now faces generic competition; Januvia faces both LOE and IRA. The vaccine and hospital moats are real but narrower and more contested than the headline franchise.

Verdict: a real but rented moat. Durable competitive advantage exists at the engine level (oncology clinical-evidence scale, vaccine manufacturing, Animal Health diversification) but not at the molecule level for the crown jewel. This is a serial-patent-cliff business, full stop. Post-2028, the entire thesis rests on whether the R&D/BD engine can replicate the AbbVie baton-pass — and unlike AbbVie, Merck’s replacement portfolio is largely pre-launch and unproven at scale. The moat is the engine, not the drug; the question is whether the engine is strong enough.

5. Growth History and Forward Opportunities

History. Revenue grew from $48.7B (2021, post-Organon spin) to $59.3B (2022), $60.1B (2023), $64.2B (2024), and $65.0B (2025) — but growth has decelerated to a crawl (+1.3% in 2025), and it has been heavily Keytruda-dependent and M&A-augmented. In 2025, Keytruda (+$2.2B) and Animal Health (+8%) carried essentially all of the company’s net growth, which was nearly fully offset by Gardasil (−$3.35B), Lagevrio (−$0.58B), and emerging LOEs. Strip Keytruda out and the base business is treading water.

The forward bet — management’s “$70B phoenix.” On the Q4-2025 and Q1-2026 calls, CEO Rob Davis framed “line of sight to over $70 billion of potential commercial opportunity by the mid-2030s” from “20-plus anticipated new growth drivers,” explicitly “more than double consensus 2028 peak Keytruda revenue of $35 billion.” The honest caveats, in management’s own words: the figure is non-risk-adjusted (gross, pre-probability), ~10 programs are expected to be “substantially clinically de-risked over the next two years,” and the full portfolio is to be de-risked “by the end of 2027.” Applying standard pharma probability-of-success haircuts, the risk-adjusted number is far lower — but the breadth is real, and the 2026–2027 readout cluster is the catalyst window the entire thesis hinges on.

The de-risked, already-ramping drivers:

• Winrevair (sotatercept, PAH) — the clearest win. $1.44B in its first full year (from $419M), $525M in Q1-2026 alone (+88%), with >9,100 patients started. A genuinely novel mechanism (activin-signaling/vascular remodeling, not a vasodilator). The HYPERION/CADENCE program opens a potentially much larger pulmonary-hypertension-in-heart-failure (HFpEF) population, where a Phase II hazard ratio of 0.18 on time-to-clinical-worsening is striking. Street peak estimates commonly run $5–6B+.
• Capvaxive (21-valent adult pneumococcal) — $759M from $97M, real traction.
• Welireg (HIF-2α oral, oncology) — $716M, +41%, with adjuvant RCC label expansions pending (though note the LITESPARK-012 frontline-combo failure as a yellow flag).

The unproven, mostly-acquired pipeline that must actually fill the hole:

• Daiichi Sankyo ADCs — ifinatamab deruxtecan (B7-H3, PDUFA Oct-2026 in small-cell lung), patritumab deruxtecan (HER3, Phase III breast), raludotatug deruxtecan (Phase III ovarian).
• sac-TMT / sacituzumab tirumotecan (TROP2 ADC, Kelun-partnered) — Merck’s flagship ADC with 16–17 Phase III studies, first positive Phase III data emerging in endometrial and lung.
• Enlicitide decanoate (oral PCSK9) — potentially the first oral PCSK9 inhibitor, a possibly very large cardiovascular opportunity, CNPV-granted, approval possible 2H-2026.
• Tulisokibart (TL1A, from the $10.8B Prometheus deal) — Phase III in ulcerative colitis, Merck’s immunology bet, still unapproved.
• MK-1406 / CD388 (from the $9.2B Cidara deal) — first-in-class long-acting flu prophylaxis, >$5B potential per management, Phase III.
• Ohtuvayre (COPD, from the $10B Verona deal) — novel COPD maintenance therapy, early launch.
• LaNova LM-299 (PD-1×VEGF bispecific) — Merck’s entrant into the ivonescimab-style bispecific race, deliberately approached with caution after mixed competitor data.
• Plus the HIV franchise (once-weekly oral islatravir/lenacapavir with Gilead — Phase III met endpoints June 2026; monthly oral PrEP), the Moderna-partnered individualized cancer vaccine (V940/intismeran), and TERN-701 (CML) from the pending Terns acquisition.

Crucially, several of these carry U.S. patent runways into the late 2030s–2041 (sac-TMT 2040, enlicitide 2040, tulisokibart 2040), so a handful of successes would genuinely re-establish a post-Keytruda exclusivity base.

Verdict: high-breadth, unproven-magnitude growth — currently insufficient and back-end-loaded. Winrevair + Capvaxive + Welireg are de-risked and growing, but their combined ~$3B is a fraction of the ~$15–20B Keytruda gross-profit hole. The $70B claim is an aspiration whose credibility is entirely contingent on the 2026–2027 readouts. The quality of growth is improving (more novel mechanisms, real launches) but the quantity that is proven is not yet enough.

6. Financial Quality

Revenue and the concentration problem. Total revenue of $65.0B (2025) is high-quality in margin but low-quality in concentration. Keytruda is 49% of company sales and ~55% of the Pharmaceutical segment, and — because oncology biologics carry the richest margins — an even larger share of gross profit. The Pharmaceutical segment earns a ~79% segment-profit margin; Animal Health ~33%.

Margins. Gross margin was 74.8% on a GAAP basis in 2025 (down 150bps, depressed by restructuring/accelerated depreciation in cost of sales and vaccine inventory write-downs) but ~82% on the non-GAAP basis management guides to. Underlying operating margin runs in the high-30s%-to-40% range once IPR&D and restructuring charges are stripped; the headline R&D-to-sales ratio swings wildly (24% in 2025, 28% in 2024, 51% in 2023) only because of acquired-IPR&D charges — “core” internal research (Merck Research Laboratories) is a steady ~$10.8B, ~16–17% of sales.

The single most important quality-of-earnings point: GAAP and even non-GAAP EPS are distorted by serial IPR&D expensing. Merck’s business-development machine routinely acquires single assets structured as asset acquisitions, which are expensed immediately to R&D with no tax benefit rather than capitalized. The magnitudes are large and recurring: $9.0B for Cidara in Q1-2026 ($3.62 per share, producing a GAAP net loss that quarter); ~$3.5B in 2024 (EyeBio/Curon/Harpoon); $11.4B in 2023 (Prometheus/Imago — which collapsed FY2023 GAAP EPS to $0.14). Unusually, Merck does not add these charges back to its non-GAAP EPS — it considers them recurring — so neither metric is a clean operating run-rate. This is why:

• FY2025 GAAP diluted EPS was $7.28 and non-GAAP $8.98.
• TTM GAAP EPS is only ~$3.55 — the entire collapse from a ~$9 run-rate is the $3.62 Cidara charge plus the timing of quarters, not operating deterioration.
• FY2026 non-GAAP guidance of $5.04–5.16 still includes the $3.62 Cidara charge; the underlying clean figure is ~$8.7–8.8, and the pending Terns deal will layer on another ~$2.35-per-share charge.

The investment implication is decisive: headline P/E ratios on MRK are nearly meaningless; one must value the clean ~$8.7–9.0 operating earnings power, which is itself arguably understated because the expensed IPR&D represents investment, not operating cost.

Cash flow. Operating cash flow was $16.5B in 2025 (down from $21.5B in 2024) — the decline driven by working-capital timing and the absence of the prior year’s large non-cash IPR&D add-back, not deterioration. Free cash flow (OCF − $4.1B capex) was ~$12.4B, comfortably covering the $8.2B dividend but not dividend + buyback + ~$9B/year of M&A — the gap is debt-funded. OCF/NI conversion of ~0.9× is healthy; there is no troubling NI/OCF divergence.

Balance sheet. Investment-grade and comfortable: $14.6B cash, ~$49.3B total debt, ~$35B net debt, net-debt/EBITDA ~1.3× (GAAP) / ~1.1× (adjusted). Debt is well-laddered with no maturity wall; the 2025 +$12B debt increase funded the Verona acquisition and shareholder returns. Goodwill + intangibles of ~$48B (35% of assets) reflect the acquisition-heavy strategy; pensions are well-funded; the post-Organon-spin capital structure is clean. One item to watch: $5.7B of pre-launch/long-dated inventory parked in “Other Assets,” carrying write-down risk (vaccine write-downs already hit 2025).

Returns on capital. ROE ~35–37%, ROIC ~21% (GAAP) — genuinely high. Caveats: ROE is flattered by ~$63B of cumulative buybacks shrinking the equity base, and ROIC is flattered by the fact that much acquired pipeline was expensed (never entering invested capital) while $48B of goodwill/intangibles from other deals sits on the books. On any basis, this is a high-return franchise; the open question is whether the cliff-defense capital deployment sustains those returns.

Verdict: economics are excellent and improve with scale at the franchise level, but reported earnings are heavily distorted by recurring deal charges, the revenue base is dangerously concentrated, and the cash flows — while strong — do not self-fund the current dividend-plus-buyback-plus-M&A cadence.

7. Capital Allocation

The strategy is explicit and deadline-driven: reinvest in R&D/BD first, grow the dividend second, buy back stock as the residual. The defining feature of the last five years is a >$45–50B cumulative deployment of cash plus expensed IPR&D into cliff-defense M&A — Acceleron/Winrevair (~$11.5B, 2021), Prometheus/TL1A ($10.8B, 2023), Verona/Ohtuvayre ($10B, 2025), Cidara/MK-1406 ($9.2B, 2026), plus EyeBio, Curon, Harpoon, Imago, LaNova, and the ~$22B-potential Daiichi ADC alliance — and the pending Terns deal.

M&A track record — genuinely mixed. Acceleron is a clear, validating win: sotatercept became Winrevair, the fastest-growing launch in the portfolio, proving Merck can buy and commercialize. Verona (a commercial-stage COPD product) is the most defensible recent deal because it bought revenue, not a clinical lottery ticket. But the larger pattern is concerning. Merck is buying late-cycle, contested biotech assets under a hard 2028 deadline — the worst possible negotiating position (Marathon: “high returns attract capital; urgency destroys discipline”). The shift toward single-asset, fully-expensed asset acquisitions (Cidara $9.2B, Curon, Harpoon, EyeBio) means paying cash for binary clinical optionality with no tax shield and immediate P&L hit. The two largest clinical bets — Prometheus/tulisokibart and Cidara/MK-1406 — remain unapproved. Whether this was prudent diversification of cliff risk or expensive scattershot buying will be settled only by the readout outcomes.

Dividend. Per-share dividends rose from $2.96 (2023) to $3.12 (2024) to $3.28 (2025), with the quarterly raised to $0.85 ($3.40 annualized run-rate) — a ~2.8% yield. Payout is ~45% of GAAP net income, ~66% of FCF, ~35–40% of non-GAAP EPS. Note: Merck is not a Dividend Aristocrat — it reset the dividend after the 2021 Organon spin-off, breaking the continuous-increase streak; it has raised every year since. The dividend itself is well-covered and defensible through the cliff; the growth rate is the variable at risk if post-2028 free cash flow compresses.

Buybacks. Repurchases jumped from ~$1.3B/year (2021–2024) to $5.1B in 2025, opportunistically buying a stock that had fallen toward multi-year lows — a signal of management’s “the market is over-discounting the cliff” view. But the 2026 guide drops back to ~$3.0B (to absorb Cidara), confirming buybacks are the flex/residual line. Net share count fell only ~2% in 2025; this is not an aggressive return-of-capital program for a ~$296B-cap company.

Internal vs. external R&D — a tacit admission. Of $15.8B total 2025 R&D, only ~$10.8B was internal; the rest was external BD. The flagship post-cliff assets — Winrevair, Ohtuvayre, TL1A, the ADCs, the flu antiviral — are overwhelmingly bought-in. This signals that Merck’s internal labs, however productive, are not generating enough late-stage replacement revenue on their own for the Keytruda cliff. The dependence on external innovation is the central capital-allocation question.

Compensation and incentives (2026 proxy). CEO Robert Davis earned $20.8M in 2025, with ~92% of target compensation variable/at-risk. The annual scorecard weights Revenue 35% / Pre-Tax Income 35% / Pipeline milestones 20% / Sustainability 10%; long-term PSUs are 50% cumulative EPS + 50% relative TSR over three years, formulaic with no discretion, and no repricing is permitted. Say-on-pay support was ~91%. This is well-structured and long-term-aligned — the relative-TSR half and pipeline weighting correctly incentivize cliff defense. One structural concern: the PSU EPS target appears to be non-GAAP (the Pay-vs-Performance company-selected measure is non-GAAP EPS), which means the multi-billion-dollar acquired-IPR&D charges from management’s own deals do not reduce executive payouts — management is insulated from the GAAP cost of its dealmaking. A second, milder concern: Davis holds combined Chairman/CEO/President roles, partially mitigated by an independent Lead Director.

Insider behavior — a notable absence of conviction. Across 194 Form 4 filings in 2024–2026, there were zero open-market purchases — every transaction is a routine grant, option exercise, or tax-withholding. Despite the stock sitting near multi-year lows on cliff fear — exactly the setup where confident insiders buy — not one executive or director bought a share. This is an absence of a bullish signal (common at mega-caps, but conspicuous here).

Verdict: mixed, leaning cautious, with the jury out on the biggest bets. Capital-return hygiene is clean and the dividend is safe; the Acceleron/Winrevair win demonstrates real competency. But Merck is deploying enormous capital into expensive, mostly-pre-approval assets under deadline pressure, the replacement pipeline is bought rather than built, and management’s comp insulates it from the GAAP cost of that strategy. Management has earned the benefit of the doubt on commercialization; it has not yet earned it on the price and concentration of its recent clinical bets.

8. Changes and Headwinds — Last Two Years

The defining strategic shift has been the pivot from a Keytruda-cash-harvesting company to a frantic cliff-defense diversification campaign — the $10B Verona acquisition (Oct-2025, Ohtuvayre/COPD), the $9.2B Cidara acquisition (Jan-2026, long-acting flu), the pending Terns deal (CML), the LaNova bispecific licensing, and the continued build-out of the Daiichi ADC alliance and the Winrevair franchise. The launch and rapid ramp of Winrevair (2024) and the U.S./EU approvals of Keytruda Qlex (the subcutaneous lifecycle hedge) are the two most thesis-relevant positive developments.

The Gardasil shock. Beginning mid-2024, shipments from Merck’s Chinese distributor (Chongqing Zhifei) to vaccination points fell sharply, producing a channel-inventory glut; Merck paused all China shipments in February 2025 and had not resumed as of the FY2025 10-K, guiding that China Gardasil sales “will not materially increase in 2026.” Compounding the inventory problem, a domestic Chinese 9-valent HPV vaccine was approved in June 2025 — a permanent competitive impairment. Gardasil fell −39% in 2025 (−$3.35B) and is best treated as structurally impaired, not cyclically depressed. (~135 U.S. Gardasil product-liability cases are pending in an MDL — a manageable tail risk.)

LOEs and IRA arriving together. Januvia/Janumet reaches U.S. LOE in 2026 (Merck expects to “lose nearly all U.S. sales”) and is subject to IRA price-setting (Januvia from Jan-2026, Janumet from Jan-2027); Bridion faces generics; the IRA Part D redesign is compressing net prices on the new launches Merck most needs to grow. FY2026 guidance absorbs a ~$2.5B headwind from this LOE/IRA/restructuring bucket.

Pipeline news flow (June 2026). Positive: the once-weekly oral islatravir/lenacapavir HIV regimen (with Gilead) met its Phase III endpoints. Negative: the KEYNOTE-D46/EVOKE-03 trial of Trodelvy + Keytruda in first-line metastatic NSCLC was discontinued for futility — a reminder that not every combination bet works and that the 2026–2027 readout cluster will produce misses as well as hits.

Leadership. Davis (CEO since 2021) reorganized the commercial leadership in 2026 to support the diversification strategy; succession planning is active. No destabilizing turnover.

Verdict: the changes net to a weakened near-term thesis with optionality. The Gardasil impairment and the simultaneous LOE/IRA arrivals are real, present headwinds; the Winrevair ramp, Qlex approvals, and pipeline breadth are real, future-dated offsets. The next 18–24 months of readouts will determine which dominates.

9. Risk Analysis

The risk profile is bimodal and concentrated: a cluster of high-impact risks (the cliff, IRA, Qlex, pipeline) all resolve in roughly the same 2028–2029 window, which is what makes the stock both cheap and genuinely risky rather than simply mispriced. The catastrophic-loss risk is low (fortress balance sheet, broad portfolio, no solvency issue); the value-impairment risk — a permanent step-down in earnings power if the cliff is not filled — is real and is the core bear case.

10. Valuation Discussion (Embedded Expectations)

We assign no price target and make no recommendation in this section; we frame what the market is underwriting.

The multiple, cleaned up. At ~$119, MRK’s market cap is ~$296B and EV ~$340B. The headline trailing P/E of 33× and the screen readings flagging MRK as “rich vs. its own history” (P/E 76th, P/B 90th, P/S 91st percentile) are artifacts of the IPR&D-charge-depressed TTM GAAP EPS of $3.55 and of margin-mix effects (P/S and P/B rise mechanically as Keytruda lifts margins — the least informative multiples here). On clean operating earnings — FY2026 underlying non-GAAP EPS of ~$8.7–9.0 (stripping the $3.62 Cidara charge embedded in the $5.04–5.16 guide) or consensus forward EPS of ~$9.56 — MRK trades at ~12.5–13.5× forward earnings, near the cheap end of its decade history and of large-cap pharma.

Peer context (forward P/E, 2026-06-10): MRK ~12.5×, ABBV ~13.8×, JNJ ~18.8×, LLY ~25.5×, Bristol Myers ~9.0×. On EV/EBITDA: MRK ~11.4×, ABBV ~15.4×, JNJ ~17.7×, BMY ~7.9×. The market is pricing Merck closer to cliff-stricken Bristol Myers than to a durable compounder — a ~30% discount to a “normal” large-cap-pharma multiple of ~15–16× and a ~45% discount to the S&P 500.

What the price embeds. A ~12.5× forward multiple for a business earning 82% gross margins and 35% ROE is the market saying: we do not believe these earnings are durable. Reverse-engineering, the discount to a normal ~15–16× multiple implies the market expects roughly flat-to-declining EPS through and beyond the 2028 cliff — i.e., it is underwriting that the pipeline will not fully fill the Keytruda hole, and that earnings power steps down rather than compounds. The market is, in effect, treating the $70B pipeline as worth a heavy probability haircut and Qlex as a partial, uncertain shield.

Scenario analysis (illustrative, on clean non-GAAP EPS):

What the market is underwriting correctly vs. incorrectly. Correctly: that the cliff is real, that Keytruda concentration is dangerous, that the replacement pipeline is unproven, and that Gardasil is impaired — all justify a discount. Possibly incorrectly: that Merck’s commercialization engine (proven by Winrevair), its 20+ shots on goal, the late-2030s patent runways of the pipeline winners, and ~$12B+ of free cash flow per year deserve to be valued as a near-melting franchise. The variant view is that breadth plus a 13× multiple is a margin of safety the BMY-style pricing ignores — provided the 2026–2027 readouts deliver.

Verdict: Merck is cheap on clean earnings and dear on appearances. The valuation already discounts a hard landing; the question is not whether the cliff is priced (it is) but whether it is over-priced — and that cannot be answered without the pipeline de-risking that is still 12–24 months away.

11. Variant Perception

Consensus belief. The Street is split but leans cautiously constructive: a ~12.5× forward multiple, a ~$130 average analyst target, and a rating distribution skewed to buy/hold (12 strong-buy, 11 hold, 0 sell). The consensus narrative is “high-quality franchise, real cliff, cheap enough that the risk is largely priced, wait for pipeline catalysts.” MRK is widely held by income and quality-value investors; short interest is negligible (~1.2% of float), so this is not a crowded short — the variant-perception tension is long-side conviction, not a squeeze.

The strongest bull case. Merck is a stealth grower hiding behind a charge-distorted P&L. You are paying ~13× clean earnings and getting a 2.8% growing dividend, a fortress balance sheet, an elite commercialization engine (Winrevair proves it), and a free option on 20+ pipeline assets — several of which (oral PCSK9, the Daiichi ADCs, sac-TMT, Winrevair-in-HFpEF, TL1A) could individually be multi-billion-dollar drugs with patent runways into the late 2030s. Unlike Bristol Myers (priced similarly at ~9×), Merck has both more shots on goal and a demonstrated ability to convert them. As the 2026–2027 readouts de-risk the bridge, the multiple re-rates toward 15–16× and the stock works even if Keytruda erodes on schedule — the AbbVie playbook, where the market eventually paid up for the baton-pass.

The strongest bear case. This is a serial-patent-cliff treadmill entering its steepest cliff with the weakest possible defense: the crown jewel is ~49% of revenue, its replacement (Qlex) is the same molecule reformatted and defends at most 30–40%, the rest of the “phoenix” pipeline is bought, not built, mostly pre-approval, and was acquired at high prices under deadline pressure (a value-destructive negotiating position). Gardasil — the supposed second pillar — is structurally broken in China. Management’s $70B number is non-risk-adjusted vapor until proven, not one insider has bought a share, and “breadth” is not the same as “scale.” Pharma history is littered with diversification-by-acquisition campaigns that diluted returns and never replaced the lost crown jewel. At 13× falling earnings, the stock is a value trap, not a value.

The 3–5 assumptions that matter most:

1. Qlex conversion — does subcutaneous Keytruda actually retain 30–40% of the franchise against payer pressure? (Bull needs yes; bear assumes no.)
2. Pipeline hit rate 2026–2027 — do 2–3 of {TL1A, the ADCs, oral PCSK9, sac-TMT, Winrevair-HFpEF} convert to approvable blockbusters?
3. Risk-adjusted value of the $70B — what is the PoS-weighted, net-of-IRA number, and does it cover the ~$15–20B Keytruda hole?
4. Gardasil terminal value — is there any China recovery, or is ~$5B the new, still-eroding base?
5. The multiple — does the market re-rate clean earnings toward 15–16× on de-risking, or de-rate toward 10–11× on misses?

Falsification. The bull case is falsified if Qlex conversion visibly stalls and/or two-plus marquee readouts miss in 2026–2027, confirming an earnings cliff. The bear case is falsified if the de-risking cluster delivers and clean EPS holds flat-to-up through 2028–2029, making the post-cliff bridge visible before Keytruda falls.

12. Fact vs. Interpretation

13. Open Questions

1. Keytruda biosimilar field — exactly how many pembrolizumab biosimilars are in late-stage development, and from whom (Amgen, Sandoz, Samsung Bioepis, Celltrion et al.)? Not enumerated in the local filings.
2. Official Winrevair peak-sales guidance — management gives patient metrics but no explicit company peak number; Street estimates ($5–6B+) are external.
3. Qlex conversion durability — will the 30–40% target survive payer step-edits to cheaper biosimilar IV once available?
4. Risk-adjusted value of the $70B pipeline — what is the probability-weighted, net-of-IRA figure, and the 2026–2027 de-risking hit rate?
5. Gardasil China terminal value — any recovery path, or is ~$5B the new eroding base?
6. Keytruda IRA timing — precise negotiation-selection year and the magnitude of the negotiated-price haircut.
7. PSU EPS basis — GAAP or non-GAAP? (Strongly implied non-GAAP, which would insulate management from its own IPR&D charges.)
8. Normalized operating EPS — the true ex-recurring-IPR&D earnings power is materially above the reported $8.98 non-GAAP; quantifying it changes the multiple narrative.

14. What Must Be True

For the bull case to be right:

• Keytruda Qlex must convert ~30–40% of the IV franchise and hold that share against payer pressure — falsification test: Qlex sales stall or payers mandate biosimilar IV substitution within 12 months of biosimilar launch.
• At least two or three of the marquee pipeline assets (TL1A/tulisokibart, the Daiichi ADCs, sac-TMT, oral PCSK9 enlicitide, Winrevair-in-HFpEF) must convert to approvable, multi-billion-dollar drugs in 2026–2027 — falsification test: two or more pivotal readouts miss or get materially delayed, as EVOKE-03 already did.
• Clean EPS must hold roughly flat-to-up through 2028–2029, making the post-cliff bridge visible before Keytruda falls — falsification test: consensus 2029–2030 EPS estimates decline through the next eight quarters.

For the bear case to be right:

• The Keytruda cliff must prove to be a true earnings cliff — Qlex underperforms, biosimilars take >60% of the franchise quickly, and IRA compounds the hit — falsification test: Qlex exceeds 40% conversion and Keytruda-family revenue declines less than ~25% in the first two years post-biosimilar.
• The acquired pipeline must under-deliver, confirming Merck overpaid for binary optionality under deadline — falsification test: tulisokibart, MK-1406, and two ADCs all reach market and collectively clear ~$10B+ by the early 2030s.
• Gardasil and the legacy LOEs must keep eroding faster than new launches grow — falsification test: total ex-Keytruda revenue grows mid-single-digits or better for two consecutive years.

The elegance of the setup is that both falsification tests resolve in the same 2026–2029 window — which is exactly why the stock is cheap, why it is risky, and why patience (and a 2.8% dividend) is the price of admission.

15. Source Appendix

See the separate Source Appendix (below) for the full list of primary sources: Merck FY2021–FY2025 Forms 10-K, Q1-2026 Form 10-Q, 2022–2026 DEF 14A proxy statements, Form 4 insider filings, Q4-2025 and Q1-2026 earnings-call transcripts and recent conference presentations, SEC EDGAR XBRL financial data, and peer comparison data. All non-obvious facts in this note trace to a primary filing or public source listed in the source appendix.

This analysis contains no buy/sell recommendation and no price target; valuation is discussed solely as embedded market expectations and scenarios. The sole exception is the clearly-labeled “Claude’s Take” block at the top, which is the author’s own independent opinion.

APPENDIX A — Standard Diligence Questionnaire

Merck & Co., Inc. (NYSE: MRK) — Report date 2026-06-11

Supplemental to the research note. Answers are grounded in primary filings and public sources; labeled Fact / Interpretation / Assumption where it matters.

General

What thoughtful questions have other investors asked about this company? The dominant questions cluster around the Keytruda cliff: (1) How much of the ~$35B Keytruda franchise can Qlex (subcutaneous) defend, and for how long? (2) What is the risk-adjusted value of the “$70B by mid-2030s” pipeline versus management’s non-risk-adjusted headline? (3) Is the serial-acquisition strategy disciplined pipeline-building or panic spending under a deadline? (4) Will the simultaneous 2028–2029 hit (patent + IRA) produce an earnings cliff or merely a plateau? (5) Is ~12.5× clean forward earnings a margin of safety or a value trap on falling earnings? Sophisticated investors also probe the quality-of-earnings distortion from expensed IPR&D (why GAAP and even non-GAAP EPS understate operating power), and Gardasil’s China terminal value.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Interpretation: At a franchise high that is about to be tested. Keytruda is near peak (~$35B expected 2028) and is ~49% of revenue; clean earnings power (~$8.7–9.0 EPS) is near a structural high precisely because the cliff has not yet hit. This is the opposite of a depressed cyclical trough — it is a high-water mark with a known drawdown ahead.

Driven by the external environment or internal actions? Both. Internally driven by Keytruda’s indication expansion and pricing; externally pressured by IRA price-setting, biosimilar timelines, and the China/Gardasil shock. Pharma demand itself is largely non-cyclical (drugs are bought in recessions), so the volatility is patent-cycle and regulatory, not macro-cyclical.

How stable are revenues? Fact: Total revenue has been remarkably stable in aggregate ($60–65B, 2023–2025) but the composition is shifting under the surface — Keytruda and Animal Health up, Gardasil/Lagevrio/Januvia down. The aggregate stability masks a coming step-change at the 2028 cliff.

Outlook for products/services? Near-term (2026): low-single-digit revenue growth (+1–3% guided), absorbing ~$2.5B of LOE/IRA headwind. Medium-term: dominated by the cliff and the pipeline race. The honest outlook is bimodal — flat-to-down if the pipeline disappoints, resumed growth if it delivers.

How big will this market be — growing, shrinking, domestic or international? Global pharma is a large, secularly growing market (aging demographics, oncology/immunology innovation) but with deteriorating net economics from price regulation. Oncology and obesity/cardiometabolic are the fastest-growing pools; Merck is strong in oncology, building in cardiopulmonary (Winrevair), and absent in obesity (a notable gap vs. Lilly/Novo). Roughly half of revenue is ex-U.S.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? More. IO, PD-1×VEGF bispecifics, TROP2 ADCs, and TL1A are crowded arms races; biosimilars and IRA compress returns industry-wide.

How profitable is the business (ROIC, ROE)? Fact: ROE ~35–37%, ROIC ~21% (GAAP), gross margin ~82% non-GAAP, Pharmaceutical segment profit margin ~79%. Genuinely elite, with caveats (buyback-shrunken equity flatters ROE; expensed IPR&D flatters ROIC).

How profitable is the industry — competitors, barriers to entry? Very profitable in-window; barriers (patents, regulatory approval, clinical-evidence scale, manufacturing) are high but time-boxed. Key competitors: Bristol Myers, Roche, AstraZeneca, Pfizer, Johnson & Johnson, Novartis, AbbVie, and Lilly across various franchises.

Can the business be easily understood? Moderately. The economics are simple (high-margin patented drugs on a treadmill); the complexity is in the pipeline’s clinical probabilities and the patent/IRA timelines, which require specialist judgment.

Can it be undermined by foreign low-cost labor? Not labor — but by foreign manufacturing (biosimilars and generics from low-cost producers) and by domestic-substitute competition abroad (the Chinese 9-valent HPV vaccine undermining Gardasil is the live example).

Do brands matter? Less than in consumer goods. Physician/clinical-evidence trust and payer formulary placement matter more than consumer brand; at LOE, the brand provides little protection against a therapeutically identical biosimilar.

Nature of competition? Clinical differentiation, indication breadth, trial-data superiority, payer contracting, and — at LOE — price.

Customers’ switching costs? Low at the molecule level (a biosimilar switch is a formulary decision), moderate in entrenched adjuvant/perioperative oncology use where clinicians are conservative. This is the thin reed Qlex’s conversion strategy leans on.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Yes — the internally generated pipeline and brand/clinical-evidence base are expensed, not capitalized; and acquired IPR&D (Cidara, Curon, etc.) is expensed immediately, so successful acquired programs carry no balance-sheet asset. This understates economic asset value. Conversely, $48B of goodwill/intangibles from other deals is on the books.

Off-balance-sheet liabilities? Contingent: ~$1.3B IRS transition-tax dispute, Gardasil product-liability MDL (~135 cases), and contingent milestone/royalty obligations on partnered/acquired assets (Daiichi, Moderna, LaNova). Pensions are well-funded (a net asset).

How conservative is the accounting? Fact: Unusually conservative on IPR&D — Merck expenses asset acquisitions immediately and refuses to add them back to non-GAAP, depressing reported EPS below true operating power. This is the rare case where accounting conservatism understates earnings.

How CapEx-hungry? Moderate: ~$4.1B/year (~6% of sales), rising toward a planned ~$20B 2025–2029 program (>$12B U.S.) for manufacturing capacity. Lower intensity than industrials; the real “capex” is R&D + BD (~$16B/year).

Capital Allocation & Management

How much FCF, and how is it used? Fact: ~$12.4B FCF (2025). Priority order: R&D/BD reinvestment first (~$16B), dividend second (~$8.2B), buybacks as residual (~$5.1B 2025, guided ~$3.0B 2026). The dividend+buyback+M&A cadence exceeds FCF and is partly debt-funded.

Significant acquisitions recently? Yes, extensively: Verona ($10B, 2025), Cidara ($9.2B, 2026), pending Terns, plus the Daiichi ADC alliance and many bolt-ons — a >$45–50B cliff-defense campaign since 2021.

Buying back shares? Modestly — net share count fell ~2% in 2025; buybacks are opportunistic/residual, not a primary lever.

Issuing large amounts of stock to insiders? No — SBC is modest (~$0.8B/year); dilution is minimal.

Compensation policy? ~92% of CEO comp variable; annual scorecard (Revenue 35 / Pre-Tax Income 35 / Pipeline 20 / Sustainability 10), 3-year PSUs (50% cumulative EPS + 50% relative TSR). Well-aligned, with the caveat that the EPS metric is likely non-GAAP, insulating management from its own IPR&D charges.

Motivations of management? Professional managers (non-founder); Davis CEO since 2021. Incentives broadly aligned with long-term TSR and pipeline delivery. The absence of any open-market insider buying is a notable non-signal of conviction.

Valuation & Market Data

ADR, MLP, or K-1 issuer? No — a U.S. C-corporation, common stock, standard 1099 dividend treatment.

Dividend policy? Growing dividend (~$3.40 annualized, ~2.8% yield, ~45% GAAP payout); raised annually since the 2021 Organon spin reset, but not a Dividend Aristocrat (streak broken by the spin).

How profitable? Highly — see ROIC/ROE/margins above.

Net income diverging from cash from operations? Fact: Not in a quality-concerning way. The GAAP net income line is distorted by IPR&D charges (collapsing it below OCF in charge-heavy years like 2023 and Q1-2026), but this is an accounting artifact, not an earnings-quality red flag — clean OCF/NI conversion is ~0.9–1.0×.

Risks & Downside

What would cause the stock to decline? A Qlex conversion failure; pivotal pipeline readout misses (TL1A, the ADCs, MK-1406); a faster/larger Keytruda biosimilar erosion; an adverse IRA/Keytruda negotiation; continued Gardasil deterioration; or a value-destructive large acquisition.

Risk of a catastrophic loss? Low. Fortress balance sheet (~1.3× net leverage), broad portfolio, no solvency risk, deep cash generation. The realistic downside is value impairment (a permanent earnings step-down if the cliff is not filled), not ruin.

Chance of a total loss? Negligible — this is a $296B, investment-grade, cash-generative mega-cap. The risk is underperformance/de-rating, not zero.

Recent News & Events

Has the business environment changed recently? Yes: (a) Keytruda Qlex U.S./EU approvals (the lifecycle hedge); (b) the Gardasil China shipment halt and new domestic competitor (structural impairment); © Januvia IRA price-setting effective Jan-2026 + 2026 LOE; (d) the $10B Verona and $9.2B Cidara acquisitions; (e) June-2026 pipeline news — positive HIV (islatravir/lenacapavir Phase 3 met endpoints with Gilead) and negative oncology (Trodelvy+Keytruda NSCLC discontinued).

Significant acquisitions? Verona (2025), Cidara (2026), pending Terns — see above.

Change in accounting policies? None material; the consistent (and conservative) expensing of acquired IPR&D is the key feature to understand.

Recent changes — new markets, facilities, management? A ~$20B 2025–2029 capacity buildout (>$12B U.S.); 2026 commercial-leadership reorganization to support diversification; continued Winrevair/Capvaxive/Ohtuvayre launches.

APPENDIX B — Source Appendix

Merck & Co., Inc. (NYSE: MRK) — Report date 2026-06-11

All material facts in this report trace to the primary sources below. Primary (SEC filings, company transcripts, regulatory data) prioritized over secondary throughout.

A. SEC Filings — Primary (Merck & Co., Inc., CIK 0000310158)

SEC EDGAR XBRL (data.sec.gov companyconcept), accessed 2026-06-11: Revenues, NetIncomeLoss, ResearchAndDevelopmentExpense, NetCashProvidedByUsedInOperatingActivities, PaymentsToAcquirePropertyPlantAndEquipment, PaymentsOfDividendsCommonStock, PaymentsForRepurchaseOfCommonStock, StockholdersEquity, WeightedAverageNumberOfDilutedSharesOutstanding.

B. Company Transcripts & Presentations (primary management commentary)

Management commentary is treated as a hypothesis and validated against filings and financials.

C. Market & Comparative Data

• Public market data, accessed 2026-06-10: MRK price $119.09, market cap ~$294–297B, EV ~$340B, total debt $49.1B, cash $5.7B, forward P/E 12.5×, EV/EBITDA 11.4×, dividend yield ~2.85%, 52-wk range $76.66–$125.14.
• Peer comparison (public market data, 2026-06-10): ABBV (fwd P/E 13.8×, EV/EBITDA 15.4×), JNJ (18.8×/17.7×), LLY (25.5×/29.0×), BMY (9.0×/7.9×), PFE, AZN, NVS.
• Own-history valuation percentiles (2026-06-10): P/E 76th, P/B 90th, P/S 91st, composite 86th — noted as distorted by IPR&D-depressed TTM GAAP EPS.

D. Analytical Frameworks & Peer Context

• AbbVie (ABBV) — the Humira biosimilar-cliff analog, used for the “baton-pass” framework and the quality-grower-at-a-cliff multiple comparison (public filings).
• Johnson & Johnson (JNJ), Eli Lilly (LLY), Regeneron (REGN), Bristol Myers Squibb (BMY) — large-cap pharma peer context (public filings and market data).
• Analytical frameworks: Greenwald & Kahn, Competition Demystified (moat taxonomy, market-share-stability and ROIC tests); Edward Chancellor (ed.), Capital Returns / Marathon Asset Management (supply-side capital-cycle analysis — “high returns attract capital; urgency destroys discipline”).

E. Recent News (2026-06)

• Islatravir/lenacapavir once-weekly oral HIV regimen — Phase 3 ISLEND-1/ISLEND-2 met Week-48 endpoints (with Gilead), 2026-06-08 (positive).
• KEYNOTE-D46/EVOKE-03 (Trodelvy + Keytruda, 1L metastatic NSCLC) discontinued for futility, 2026-06-08 (negative).

Recent company press releases and trial-readout announcements, validated against primary sources.

This source appendix supports both the institutional memo and the public version. All non-obvious facts cited in the body trace to a dated entry in MRK_research_log.txt and to a primary source above.